In this podcast, experts explore the many challenges associated with the operationalization of global Integrated Evidence Generation Planning (IEGP) at local levels.Â
Experts from Lumanity discuss cross-functional alignment of Integrated Evidence Generation Planning (IEGP) from perspectives of strategy, clinical/regulatory, commercial and patient engagement.
As the sources of data and technologies needed to make sense of data expand, opportunities exist for further integrating RWE and HEOR alongside traditional approaches when planning data generation activities to support new product registration, access, and use.
Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
Through our lens into real-world issues that affect equitable use of industry innovations, Medical Affairs can drive the transformation of industry from a drug-centric perspective to a patient-centric perspective. This article discusses a few of these opportunities.
MAPS speaks with Liz de Somer, CEO of Medicines Australia and Sharon Winton, CEO of Lymphoma Australia to explore patient engagement from the perspectives of industry and patient associations.
All industries are rushing to harness rich data in order to drive progress, but how can the many data sources help Medical Affairs to show impact and drive improved patient outcomes?
In the final part of this four-part series, we will cover:
This Webinar series explores the fundamental concept of big data in Medical Affairs, from which sources can we retrieve this, what are the broader considerations when utilizing data in health and what impact this can have on our organizations, physicians, and patients, now and in the future. These presentations will feature real-world cases that are relevant to regional and country Medical Affairs leaders, in order to highlight long-term aspirational and short-term tangible projects.
Clinical research is typically costly for sponsors and burdensome for providers and patients. New methods and approaches, such as integrated evidence generation using real-world data networks and automated study platforms, are accelerating the path from start-up to read out.
Join presenters as they explore innovative approaches for:
At the end of the session, you will be able to:​
Over the last decade as the requirements for evidence to support the various dimensions of value assessment of medicines have strengthened and the breadth of audiences has increased, Medical Affairs is realizing more potential and bringing together its capabilities for strategy, science, and communication in powerful ways. In the rapidly evolving regulatory, technological, and scientific environment, the Medical Affairs function is uniquely positioned to coordinate the identification, prioritization, strategic planning, execution and communication of the broad variety of high-quality evidence necessary to fulfill unmet needs of clinicians, payers, reimbursement agencies, policy makers, advocacy groups, and patients.
This Standard and Guidance is intended to inform learners about the Evidence Generation function, strategic direction, and operations across multiple geographies.